DUBLIN, April 17, 2013 /PRNewswire/ --
Research and Markets announces the addition of "EpiCast Report: Epilepsy - Epidemiology Forecast to 2022" to its catalogue.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Epilepsy affects 50 million people worldwide each year and is one of the most common neurological conditions in the world (WHO, 2005). Epilepsy is defined as a collection of brain dysfunction disorders characterized by recurrent and unpredictable seizures. The prevalence of epilepsy varies among countries due to a mosaic of economic, political, and social differences. GlobalData epidemiologists expect that the number of active and lifetime prevalent cases of epilepsy will increase during the forecast period (2012-2022) in the nine markets covered. In 2012, we estimated that there was a total of 17,542,651 active prevalent cases of epilepsy in the nine markets, and GlobalData epidemiologists forecast that by 2022, the number of active prevalent cases will grow to 18,565,967. A major strength of this analysis is that the forecast methodology was consistent across the nine markets to allow for a meaningful comparison of the patient populations in each country.
Scope
- The Epilepsy EpiCast Report provide an overview of risk factors and global trends for epilepsy.
- Data is provided for the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) along with emerging marketsIndia and China.
- It includes a 10-year epidemiological forecast of active and lifetime prevalent cases of epilepsy segmented by gender, age, treatment gap, and seizure type (generalized, partial, and unknown).
Key Topics Covered
1 Tables & Figures
Read the original post:
Epilepsy - Epidemiology Forecast to 2022